Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2010
10/21/2010CA2758746A1 Gel compositions for administration of pharmaceutically active compounds
10/21/2010CA2758745A1 Compounds affecting glycemic index
10/21/2010CA2758709A1 Bioavailable compositions of amorphous alpha-(n-sulfonamido)acetamide compound
10/21/2010CA2758698A1 Vitamin d receptor agonists and uses thereof
10/21/2010CA2758638A1 Imidazolidine-2,4-dione derivatives and use thereof as a medicament
10/21/2010CA2758630A1 Imidazolidine-2, 4-dioze derivatives, and use thereof as a cancer drug
10/21/2010CA2758614A1 Fluoro substituted pyrimidine compounds as jak3 inhibitors
10/21/2010CA2758588A1 Methods of reduction of interpatient variability
10/21/2010CA2758587A1 Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4)
10/21/2010CA2758586A1 Compositions and methods for the treatment of inflammation
10/21/2010CA2758538A1 Pharmaceutical composition for treating dermatological autoimmune diseases
10/21/2010CA2758520A1 Methods of assessing activity of a polysaccharide composition
10/21/2010CA2758491A1 Naphthalene-based inhibitors of anti-apoptotic proteins
10/21/2010CA2758484A1 Anti-viral compounds
10/21/2010CA2758473A1 Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia
10/21/2010CA2758367A1 Derivatives of n-[(7-aza-bicyclo[2.2.1]hept-1-yl)-aryl-methyl]-benzamide, preparation thereof, and therapeutic use thereof
10/21/2010CA2758359A1 Fused pyrrolopyridine derivative
10/21/2010CA2758321A1 5-ht4 receptor agonist compounds for treatment of cognitive disorders
10/21/2010CA2758297A1 Compositions and methods for treating cancer
10/21/2010CA2758276A1 Macrocyclic lactone combination compositions, vaccines and methods for producing same
10/21/2010CA2758263A1 Methods for inhibiting angiogenesis with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
10/21/2010CA2758245A1 Gamma-amino-butyric acid derivatives as gabab receptor ligands
10/21/2010CA2758229A1 Sensitizing agents for cancer therapy, methods of use and methods for the identification thereof
10/21/2010CA2758136A1 Use of multi-kinase inhibitors in the treatment of vascular hyperpermeability
10/21/2010CA2758108A1 Process for preparation of endothelial receptor antagonist (bosentan)
10/21/2010CA2758005A1 Methods of treating cancers with her3 antisense oligonucleotides
10/21/2010CA2757762A1 Method and composition for treating macular degeneration
10/21/2010CA2757730A1 Combination therapy using an anti-egfr agent(s) and igf-1r specific inhibitors
10/21/2010CA2757711A1 Microrna as a biomarker of pancreatic islet beta-cell engagement
10/21/2010CA2757694A1 Delivery of oligonucleotide-functionalized nanoparticles
10/21/2010CA2757592A1 Bicyclic heterocyclyl derivatives as fgfr kinase inhibitors for therapeutic use
10/21/2010CA2757573A1 Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitors
10/21/2010CA2757496A1 Method for on-demand contraception
10/21/2010CA2757326A1 Imidazo [1,2-a]pyridine derivatives as fgfr kinase inhibitors for use in therapy
10/21/2010CA2757169A1 Milk oligosaccharide compositions and use thereof in treating infection in animals
10/21/2010CA2756820A1 Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
10/21/2010CA2756759A1 Imidazopyrazines for use as kinase inhibitors
10/21/2010CA2756685A1 Emulsions of perfluorocarbons
10/21/2010CA2756528A1 Compositions rich in omega-3 fatty acids with a low content in phytanic acid
10/21/2010CA2755554A1 Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
10/21/2010CA2755392A1 Pharmaceutical compositions
10/21/2010CA2710358A1 Methods of administering pirfenidone therapy
10/20/2010EP2241887A2 Diagnostics, drug screening and treatment for cancer
10/20/2010EP2241571A1 Stable 6-methoxy-2',3'-dideoxyguanosine, method for preparing the same and pharmaceutical composition containing the same
10/20/2010EP2241569A1 Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses
10/20/2010EP2241567A1 Bicycloamine derivative
10/20/2010EP2241565A1 Aurora kinase inhibitors compounds
10/20/2010EP2241564A1 3,8-diaminotetrahydroquinoline derivative
10/20/2010EP2241561A1 Neuroprotective, hypocholesterolemic and antiepileptic compound
10/20/2010EP2241560A2 Ascorbic acid derivatives, methods of synthesis and pharmaceutical use thereof
10/20/2010EP2241559A2 Ascorbic acid derivatives, methods of synthesis and pharmaceutical use thereof
10/20/2010EP2241558A1 Oxadiazole derivatives
10/20/2010EP2241557A1 Chinoxalin derivatives and use thereof for treating malignant and benign tumour illnesses
10/20/2010EP2241555A1 New RAC1 inhibitors as potential pharmacological agents for heart failure treatment
10/20/2010EP2241351A1 Pharmaceutical composition comprising glycerol, white soft paraffin and liquid paraffin for the treatment of uremic xerosis
10/20/2010EP2241342A2 Drug releasing coatings for medical devices
10/20/2010EP2241341A2 Drug releasing coatings for medical devices
10/20/2010EP2241334A1 Method for determination of sensitivity to anti-cancer agent
10/20/2010EP2241333A1 Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
10/20/2010EP2241329A2 Anti-interleukin-9 antibody or anti-interleukin-9 receptor antibody for treating bronchial hyper-responsiveness
10/20/2010EP2241325A1 Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
10/20/2010EP2241320A1 Aqueous compositions containing metronidazole
10/20/2010EP2241319A1 Combination of brimonidine and timolol for topical ophthalmic use
10/20/2010EP2241317A1 Domperidone at a low daily dose for use in the treatment or prevention of a disease associated with an alteration of the immune response
10/20/2010EP2241316A1 Indolone compounds useful to treat cognitive impairment
10/20/2010EP2241315A1 Pharmaceutical composition, use of 2-iminopyrrolidine derivative for production of pharmaceutical composition, and kit for treatment or amelioration of heart diseases
10/20/2010EP2241314A1 Alpha-lipoic acid nanoparticle and method for producing the same
10/20/2010EP2241313A1 Use of flavonoids to increase the bioavailability of hesperetin
10/20/2010EP2241312A1 Use of compositions comprising urea for treating microbial infections
10/20/2010EP2241310A2 Modified release formulations of emoxypine
10/20/2010EP2241308A2 Method for coating fine particle with lipid membrane
10/20/2010EP2241198A1 Mucositis prevention supplement and treatment
10/20/2010EP2241197A1 Agent and edible material for inhibiting body fat accumulation
10/20/2010EP2241196A2 Nutritional supplement comprising oligosaccharides and cysteine for treating hiv
10/20/2010EP2241195A1 A method and composition for nutritionally improving glucose control and insulin action
10/20/2010EP2240582A1 Positive controls for expression modulating experiments
10/20/2010EP2240501A1 Hydroxy-bisphosphonic acid derivatives as vector for targeting bone tissue
10/20/2010EP2240495A1 Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
10/20/2010EP2240492A1 Process for the preparation of asenapine and intermediate products used in said process
10/20/2010EP2240491A2 Compounds
10/20/2010EP2240488A1 Substituted imidazopyridazines useful as kinase inhibitors
10/20/2010EP2240487A1 Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
10/20/2010EP2240486A1 Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
10/20/2010EP2240485A1 Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
10/20/2010EP2240483A1 Pyrimidyl cyclopentanes as akt protein kinase inhibitors
10/20/2010EP2240482A1 Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals
10/20/2010EP2240481A1 (1-azinone) -substituted pyridoindoles as mch antagonists
10/20/2010EP2240480A2 Derivatives of 2-heteroaroyl-imidazol(1,2-a)pyridine,preparation thereof and therapeutic application thereof
10/20/2010EP2240476A1 Novel phenylethynyl derivatives of 8-aza-bicyclo[3.2.1]octane and their use as monoamine neurotransmitter re-uptake inhibitors
10/20/2010EP2240475A1 Thiazole derivatives used as pi 3 kinase inhibitors
10/20/2010EP2240474A1 Cyclic pyridyl-n-(1,3,4)-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
10/20/2010EP2240473A1 Substituted gamma lactams as therapeutic agents
10/20/2010EP2240472A1 2-amino-quinoline derivatives useful as inhibitors of -secretase (bace)
10/20/2010EP2240471A1 Molecules comprising a bis(heteroaryl)maleimide backbone, and use thereof in the inhibition of dde/ddd enzymes
10/20/2010EP2240469A2 Substantially pure and a stable crystalline form of bosentan
10/20/2010EP2240468A1 Selective subtype alpha 2 adrenergic agents and methods for use thereof
10/20/2010EP2240467A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
10/20/2010EP2240466A1 Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
10/20/2010EP2240463A2 2-methylene-(20s,25r)-19,26-dinor-vitamin d analogs
10/20/2010EP2240462A1 Therapeutic compounds
1 ... 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 ... 7860